Histigen (Betahistine Dihydrochloride)

Histigen is indicated for the symptomatic treatment of several vestibular conditions that cause dizziness and balance disturbances.

• Management of vertigo episodes associated with Meniere’s disease.
• Relief of recurrent spontaneous vertigo of unknown origin.
• Adjunct therapy for balance disorders linked to inner‑ear dysfunction.
• Supportive treatment to reduce the frequency of attacks in patients with fluctuating hearing loss.
• Use as part of a comprehensive plan for patients experiencing motion‑sickness related dizziness.
• May be prescribed to alleviate disequilibrium in chronic vestibular hypofunction.

• Betahistine acts as a selective histamine H1 receptor agonist while simultaneously blocking H3 receptors. H1 activation promotes vasodilation and increases capillary permeability, which enhances microcirculation in the stria vascularis of the inner ear. H3 antagonism prevents the feedback inhibition of histamine release, thereby raising endogenous histamine levels. The combined effect improves vestibular hair‑cell function and reduces endolymphatic pressure, helping to alleviate vertiginous symptoms.

Like many oral agents, betahistine may be associated with a range of adverse reactions, most of which are mild and reversible. The frequency and severity of these events vary among individuals, and most resolve after discontinuation of therapy.

Common

• Headache, often mild and transient.
• Nausea or mild stomach upset, usually short‑lived.
• Transient flushing of the face or neck.
• Light‑headedness or brief dizziness.

Serious

• Allergic skin reactions such as rash, urticaria, or angio‑edema.
• Marked hypotension or fainting episodes requiring medical attention.
• Palpitations, tachycardia, or other arrhythmias.
• Persistent vomiting or severe gastrointestinal distress.

When considering betahistine, healthcare providers evaluate several precautionary factors to ensure safe use.

• Assess cardiovascular status, especially in patients with known hypertension or arrhythmias.
• Review history of asthma or bronchospastic disease, as histamine activity may exacerbate symptoms.
• Use caution in individuals with peptic ulcer disease or severe gastrointestinal irritation.
• Evaluate renal or hepatic impairment, since clearance may be altered.
• Advise pregnant or breastfeeding women to consult a physician before initiating therapy.
• Monitor elderly patients closely due to increased susceptibility to hypotensive effects.

Betahistine can interact with other medications, influencing its efficacy or safety profile.

Avoid

• Concomitant use with potent antihistamines that block H1 receptors, which may diminish therapeutic effect.
• Combination with monoamine oxidase inhibitors (MAOIs) or other agents that significantly alter histamine metabolism.

Use with caution

• Concurrent administration of vasodilators or antihypertensive drugs, which may enhance hypotensive responses.
• Use alongside other vestibular suppressants, as additive dizziness may occur.
• Co‑administration with drugs that prolong the QT interval, requiring cardiac monitoring.
• Taking betahistine with alcohol, which can increase the risk of dizziness and flushing.